NexImmune (NEXI) Competitors $0.21 -0.01 (-6.42%) (As of 11:55 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEXI vs. SQZ, ADXS, QLGN, PBM, NMTR, HSTO, TCBP, PTEIQ, BLPH, and ELABShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include SQZ Biotechnologies (SQZ), Ayala Pharmaceuticals (ADXS), Qualigen Therapeutics (QLGN), Psyence Biomedical (PBM), 9 Meters Biopharma (NMTR), Histogen (HSTO), TC Biopharm (TCBP), PolarityTE (PTEIQ), Bellerophon Therapeutics (BLPH), and Elevai Labs (ELAB). These companies are all part of the "medical" sector. NexImmune vs. SQZ Biotechnologies Ayala Pharmaceuticals Qualigen Therapeutics Psyence Biomedical 9 Meters Biopharma Histogen TC Biopharm PolarityTE Bellerophon Therapeutics Elevai Labs NexImmune (NASDAQ:NEXI) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking. Is NEXI or SQZ more profitable? NexImmune has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets NexImmuneN/A -534.32% -213.72% SQZ Biotechnologies -369.96%-119.83%-59.90% Which has stronger valuation and earnings, NEXI or SQZ? NexImmune has higher earnings, but lower revenue than SQZ Biotechnologies. NexImmune is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexImmuneN/AN/A-$32.34M-$18.54-0.01SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61-0.01 Do institutionals & insiders hold more shares of NEXI or SQZ? 9.9% of NexImmune shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 14.9% of NexImmune shares are owned by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in NEXI or SQZ? NexImmune received 12 more outperform votes than SQZ Biotechnologies when rated by MarketBeat users. However, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 61.11% of users gave NexImmune an outperform vote. CompanyUnderperformOutperformNexImmuneOutperform Votes2261.11% Underperform Votes1438.89% SQZ BiotechnologiesOutperform Votes1066.67% Underperform Votes533.33% Which has more risk and volatility, NEXI or SQZ? NexImmune has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Do analysts prefer NEXI or SQZ? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NexImmune 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ASQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media prefer NEXI or SQZ? In the previous week, NexImmune had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for NexImmune and 0 mentions for SQZ Biotechnologies. NexImmune's average media sentiment score of 0.67 beat SQZ Biotechnologies' score of 0.00 indicating that NexImmune is being referred to more favorably in the media. Company Overall Sentiment NexImmune Positive SQZ Biotechnologies Neutral SummarySQZ Biotechnologies beats NexImmune on 9 of the 14 factors compared between the two stocks. Ad Golden CrestCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$289,000.00$6.75B$5.02B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E Ratio-0.0111.78128.4816.64Price / SalesN/A288.471,723.1677.30Price / CashN/A46.0936.9033.53Price / Book0.065.284.595.19Net Income-$32.34M$150.82M$113.94M$223.67M7 Day Performance-22.53%-0.69%110.64%2.76%1 Month Performance2.43%15.56%124.65%8.82%1 Year Performance-92.94%37.06%155.07%29.33% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.21-6.4%N/A-92.5%$289,000.00N/A-0.0170Gap DownSQZSQZ BiotechnologiesN/A$0.02flatN/AN/A$678,000.00$18.16M-0.011,620ADXSAyala PharmaceuticalsN/A$0.03+0.4%N/A-97.0%$1.16M$10,000.000.0020Analyst ForecastNews CoverageGap DownQLGNQualigen TherapeuticsN/A$0.09-7.8%N/A-86.0%$1.12M$4.98M0.0050Stock SplitNews CoverageGap DownPBMPsyence BiomedicalN/A$0.07-3.9%N/AN/A$1.11MN/A0.00N/AGap DownNMTR9 Meters BiopharmaN/A$0.07-43.0%N/AN/A$1.04MN/A-0.0220Gap DownHigh Trading VolumeHSTOHistogenN/A$0.21flatN/A-35.6%$908,000.00$19,000.00-0.087TCBPTC Biopharm0.6149 of 5 stars$1.45+10.7%N/A-99.9%$766,000.00$4.76M0.0041Gap UpPTEIQPolarityTEN/A$0.08flatN/A+1,050.0%$615,000.00$810,000.00-0.0360High Trading VolumeBLPHBellerophon Therapeutics0.3615 of 5 stars$0.04flatN/A-7.7%$440,000.00N/A-0.0420ELABElevai Labs0.7121 of 5 stars$0.02-29.4%N/AN/A$424,000.00$2.47M-0.0618Gap DownHigh Trading Volume Related Companies and Tools Related Companies SQZ Biotechnologies Competitors Ayala Pharmaceuticals Competitors Qualigen Therapeutics Competitors Psyence Biomedical Competitors 9 Meters Biopharma Competitors Histogen Competitors TC Biopharm Competitors PolarityTE Competitors Bellerophon Therapeutics Competitors Elevai Labs Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEXI) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEXI Stock Alerts